Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

Paper. Rucker JJ, Mantingh T, Kerr-Gaffney J et al.. Nature Medicine, 6 Aug 2026.

Tags: Human, RCT, Psilocybin, Depression.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 2: A placebo-controlled psilocybin trial inside England's NHS

60 people with treatment-resistant depression received a single 25 mg dose of psilocybin or a placebo, both with preparation and integration support. At week 3, depression scores were about 10 points lower with psilocybin, and the difference held at week 6. 59 of 60 people completed every follow-up.

How much weight it carries: Randomized and double-blind, but small and designed as a feasibility trial. The authors call for a larger confirmatory trial. (Humans, RCT, n = 60, Peer reviewed)

Read the original

—
Node—
Statuslive
Throughput—